Oxford, June 15, 2018 (GLOBE NEWSWIRE) — Oxford, UK, and Cambridge, MA, US, 15 June 2018 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces that Glyn Edwards, Chief Executive Officer, will present at the JMP Securities Life Sciences Conference on 21 June 2018 at 9:30am EDT in New York City.
A live audio webcast of the presentation will be available through the Investors section on the Company’s website, www.summitplc.com. A replay of the webcast will be available from the same location soon after the live presentation.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
For more information, please contact:
|Glyn Edwards / Richard Pye (UK office)||Tel:||44 (0)1235 443 951|
|Erik Ostrowski / Michelle Avery (US office)||+1 617 225 4455|
|Cairn Financial Advisers LLP (Nominated Adviser)||Tel:||+44 (0)20 7213 0880|
|Liam Murray / Tony Rawlinson|
|N+1 Singer (Joint Broker)||Tel:||+44 (0)20 7496 3000|
|Aubrey Powell / Jen Boorer|
|Panmure Gordon (Joint Broker)||Tel:||+44 (0)20 7886 2500|
|Freddy Crossley, Corporate Finance|
|Consilium Strategic Communications (UK)||Tel:||+44 (0)20 3709 5700|
|Mary-Jane Elliott / Jessica Hodgson /||firstname.lastname@example.org|